A low dose blend of the non-steroidal anti-inflammatory drug celecoxib and the cholesterol-lowering medication Lipitor dramatically limited the incidence of invasive and non-invasive colon adenocarcinomas, said Bandaru Reddy, D.V.M., Ph.D., research professor at Rutgers University, Piscataway, N.J.
"The combination of these drugs given to laboratory animal models inhibited 95 percent of the tumors that developed in untreated animals," Reddy said. "When used together, the drugs were most effective at doses substantially lower than when used alone.
"Using a combination of low doses of these chemopreventive agents that have differing action may be the most effective way to maximize the anti-cancer effect of the drug while also minimizing toxicity or harmful side effects."
Reddy's studies were conducted in an animal model that closely represents pathogenic, molecular and genetic events that occur in the development of cancer in the human colon. The doses of the drug combination ingested by the experimental rats were the equivalent of 120 mg/day for celecoxib and 40 mg/day for Lipitor.
By itself, celecoxib at 600 parts per million (ppm) in the diet reduced the incidence, as well as the number, of colon adenocarcinomas by 80 percent. Lipitor at 150 ppm alone reduced tumor incidence by 31 to 41 percent.
Together, at only 300 ppm of celecoxib and 100 ppm Lipitor, the drugs reduced invasive and non-invasive adenocarcinomas by 95 percent. Low doses of Lipitor and celecoxib in combination suppressed invasive adenocarcinomas, sugg
Contact: Russell Vanderboom, Ph.D.
American Association for Cancer Research